The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | The future role of SBRT with immunotherapy in early-stage NSCLC
Andrea Filippi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy explores the evolving role of combining stereotactic body radiotherapy (SBRT) with immunotherapy in early-stage non-small cell lung cancer (NSCLC), particularly in patients who are elderly, frail, or unsuitable for surgery or chemotherapy. He highlights the rationale behind this approach, where it can reduce the risk of distant relapse where SBRT alone may be insufficient. However, key challenges include competing risks from non-cancer-related mortality, small tumour sizes already effectively treated with SBRT alone, and the prolonged immunotherapy maintenance. He emphasizes the need for larger, adequately powered trials to better identify patients who may benefit most. Notably, he refers to a study using a four-cycle immunotherapy regimen as particularly promising and potentially more feasible in this vulnerable population. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
